Advanced Life Sciences (OTCBB:ADLS)
Intraday Stock Chart
Today : Tuesday 17 August 2010
Advanced Life Sciences Holdings, Inc. (OTC Bulletin
Board: ADLS), a biopharmaceutical company engaged in the discovery,
development and commercialization of novel drugs in the therapeutic
areas of infection, oncology and respiratory diseases, today announced
that the Company will participate in the 50th Interscience Conference on
Antimicrobial Agents and Chemotherapy (www.icaac.org). The International conference will be held in Boston, Massachusetts, September 12–15, 2010.
(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
As an exhibitor at this year's conference, Advanced Life Sciences
will update and interact with more than 10,000 physicians, researchers
and other healthcare professionals from around the globe who will gather
at the 50th ICAAC to focus on solutions to the problem of infectious
disease. Data on the Company's lead product, Restanza™ (cethromycin),
its novel once-daily oral antibiotic, will be presented showing the
drug's efficacy against 30 strains of Burkholderia pseudomallei, a
serious, life-threatening bacterial pathogen that is also a potential
agent of biological warfare or bioterrorism, and is listed on the
Centers for Disease Control list as a Category B bioterrorism agent.
Restanza showed significant in vitro activity against clinical and
environmental strains of B. pseudomallei as measured by minimal
inhibitory concentration (MIC), the lowest concentration of an
antimicrobial that will inhibit the visible growth of a microorganism
after 24 hours of incubation. Restanza demonstrated antibacterial
activity with MIC values ranging from 0.5−8 ug/ml and an MIC90 value of 4
ug/ml. Most notably, Restanza also demonstrated positive activity
against strains that were resistant to a commonly used antibiotic,
azithromycin, for which MIC values were all greater than 64 ug/ml.
About Restanza
Restanza is a novel oral once-a-day antibiotic that is in late stage
development for the treatment of community acquired bacterial pneumonia
(CABP) and biodefense pathogens. It has shown higher in vitro potency
and a broader range of activity than macrolides against Gram-positive
bacteria including CA-MRSA and pathogens associated with respiratory
tract infections and appears to be effective against penicillin-,
macrolide- and fluoroquinolone-resistant bacteria. Restanza's
demonstrated potency and ability to overcome bacterial resistance may be
due to its mechanism of action resulting in specificity for its
bacterial target. In addition to its utility in CABP, Restanza is also
being investigated for the prophylactic treatment of inhalation anthrax
post-exposure and other high priority biodefense pathogens, including
plague and tularemia. The FDA has designated Restanza as an orphan drug
for the prophylactic treatment of inhalation anthrax post exposure, as
well as for use in treating plague and tularemia, but the drug is not
yet approved for these or any other indications.
Advanced Life Science recently announced that it has reached agreement with the United States
Food and Drug Administration (FDA), under the Special Protocol
Assessment (SPA) process, on the design of its planned Phase 3 study of
Restanza to treat CABP.
About Burkholderia pseudomallei
Burkholderia pseudomallei is a Gram-negative, rod-shaped bacteria,
and is the causative agent of the disease melioidosis. This bacterium
can be found in contaminated water, soil and on market produce. It
causes deadly infectious diseases endemic to Southeast Asia and northern Australia,
and which may occur in other tropical and subtropical regions.
Transmission to humans and animals occurs through direct contact with
the organism via ingestion, inhalation, or through open wounds and skin
abrasions. Treatment of this disease requires prolonged therapy with
antibiotics. Few antibiotics are effective against this disease, and
there is currently no effective vaccine. The severe course of infection,
high mortality, aerosol infectivity and worldwide presence of this
pathogen has resulted in its inclusion as a potential agent of
biological warfare or bioterrorism, and is listed on the Centers for
Disease Control list as a Category B bioterrorism agent.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the
discovery, development and commercialization of novel drugs in the
therapeutic areas of infection, cancer and respiratory diseases. The
Company's lead candidate, Restanza, is a novel once-a-day oral
antibiotic in late-stage development for the treatment of respiratory
tract infections including CABP and biodefense pathogens including
anthrax, plague and tularemia. For more information, please visit us on
the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.